Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHoogendijk, Arie J.-
dc.contributor.authorWiewel, Maryse A.-
dc.contributor.authorVught, Lonneke A. van-
dc.contributor.authorScicluna, Brendon P.-
dc.contributor.authorBelkasim-Bohoudi, Hakima-
dc.contributor.authorHorn, Janneke-
dc.contributor.authorZwinderman, Aeilko H.-
dc.contributor.authorKlein Klouwenberg, Peter M.C.-
dc.contributor.authorCremer, Olaf L.-
dc.contributor.authorBonten, Marc M.J.-
dc.contributor.authorSchultz, Marcus J.-
dc.contributor.authorPoll, Tom van der-
dc.identifier.citationHoogendijk, A. J., Wiewel, M. A., van Vught, L. A., Scicluna, B. P., Belkasim-Bohoudi, H., Horn, J., ... & van der Poll, T. (2015). Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients. Critical Care, 19(1), 1-11.en_GB
dc.description.abstractIntroduction: Fractalkine is a chemokine implicated as a mediator in a variety of inflammatory conditions. Knowledge of fractalkine release in patients presenting with infection to the Intensive Care Unit (ICU) is highly limited. The primary objective of this study was to establish whether plasma fractalkine levels are elevated in sepsis and associate with outcome. The secondary objective was to determine whether fractalkine can assist in the diagnosis of infection upon ICU admission.en_GB
dc.description.abstractMethods: Fractalkine was measured in 1103 consecutive sepsis patients (including 271 patients with community-acquired pneumonia (CAP)) upon ICU admission and at days 2 and 4 thereafter; in 73 ICU patients treated for suspected CAP in whom this diagnosis was refuted in retrospect; and in 5 healthy humans intravenously injected with endotoxin.en_GB
dc.description.abstractResults: Compared to healthy volunteers, sepsis patients had strongly elevated fractalkine levels. Fractalkine levels increased with the number of organs failing, were higher in patients presenting with shock, but did not vary by site of infection. Non-survivors had sustained elevated fractalkine levels when compared to survivors. Fractalkine was equally elevated in CAP patients and patients treated for CAP but in whom the diagnosis was retrospectively refuted. Fractalkine release induced by intravenous endotoxin followed highly similar kinetics as the endothelial cell marker E-selectin.en_GB
dc.description.abstractConclusions: Plasma fractalkine is an endothelial cell derived biomarker that, while not specific for infection, correlates with disease severity in sepsis patients admitted to the ICU.en_GB
dc.publisherBioMed Central Ltd.en_GB
dc.subjectBiochemical markers -- Diagnostic useen_GB
dc.subjectChemokines -- Immunologyen_GB
dc.subjectIntensive care unitsen_GB
dc.subjectOutcome assessment (Medical care)en_GB
dc.subjectSepticemia -- Diagnosisen_GB
dc.titlePlasma fractalkine is a sustained marker of disease severity and outcome in sepsis patientsen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.contributor.corpauthorMARS Consortiumen_GB
dc.publication.titleCritical Careen_GB
Appears in Collections:Scholarly Works - FacHScABS

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.